PRESCRIPTION ANALYSIS IN THE PATIENTS ADMITTED TO THE EMERGENCY MEDICINE DEPARTMENT AT TERTIARY CARE TEACHING HOSPITAL
AbstractIntroduction: The Emergency Medicine Department presents distinct challenges, both diagnostic uncertainty and time constraints. Promptly administering the right drugs in this setting can be crucial for saving lives. Hence, we conducted a study to analyse the prescriptions in the patients admitted to Emergency Medicine Department. Method: This is a prospective, observational single center study conducted at the Emergency Medicine department for one year. The study was started after approval from Institutional Review Board (IRB). All patients of any gender and any co-morbidities admitted to emergency medicine department were included in the study. Results: In this study, total 305 patients included, out of which majority 79 (25.9%) patients were in the age young group 31-40 years. Gender distribution depicts 262 (85.9%) and 43 (14.09%) were males and females respectively. Two wheeler accidents 119 (39.01%) were the most common. Total 186 (64.13%) patients having GCS score 11-15. Pantoprazole was the most commonly prescribed drug, prescribed in 200 (81.96%) prescriptions. Ondansetron was in used in 90 (28.19%) patients. Cefixime is used in 70 (22.95%), ofloxacin in 30 (9.83%). The fixed drug combination, Glipizide + Metformin was used in 36 (11.80%) patients. Conclusion: Our study provides various insights into the analysis of prescribing drugs in the uniquely challenging environment of the Emergency department. The prescribed medications in the study were as per the patient’s condition. We propose that future studies should be conducted to explore the rational management of patients.
Article Information
24
829-836
582 KB
232
English
IJPSR
Harsh Joshi, Sravya Pinnamaneni, Sapna Gupta * and Kartik Shah
Department of Emergency Medicine, SVP Hospital, NHL Municipal Medical College, Ahmedabad, Gujarat, India.
sapna_gupta76@yahoo.com
26 July 2022
13 October 2023
06 December 2023
10.13040/IJPSR.0975-8232.15(3).829-36
01 March 2024